Newborn screening for 21-hydroxylase deficiency: results of CYP21 molecular genetic analysis

J Pediatr. 1997 Aug;131(2):328-31. doi: 10.1016/s0022-3476(97)70178-1.

Abstract

Blood samples for plasma steroid hormone determinations and molecular genotype analysis of the 21-hydroxylase gene (CYP21) were obtained from 15 infants identified through a voluntary newborn screening program. Mutations were identified on both CYP21 alleles in 12 (80%) of 15 infants; all had confirmatory plasma 17-hydroxyprogesterone concentrations > 3500 ng/dl. No patient was found to carry mutations associated with late-onset 21-hydroxylase deficiency. Newborn screening hastened diagnosis in eight infants.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 17-alpha-Hydroxyprogesterone / blood
  • Adrenal Hyperplasia, Congenital* / diagnosis
  • Adrenal Hyperplasia, Congenital* / genetics
  • Adrenal Hyperplasia, Congenital* / prevention & control
  • Alleles
  • Androstenedione / blood
  • Exons / genetics
  • Female
  • Gene Conversion / genetics
  • Genotype
  • Humans
  • Infant, Newborn
  • Introns / genetics
  • Male
  • Mineralocorticoids / therapeutic use
  • Molecular Biology
  • Mutation / genetics
  • Neonatal Screening*
  • Nucleic Acid Hybridization
  • Phenotype
  • Polymerase Chain Reaction
  • Polymorphism, Restriction Fragment Length
  • Polymorphism, Single-Stranded Conformational
  • Progesterone / blood
  • RNA Splicing / genetics
  • Sequence Analysis, DNA
  • Steroid 21-Hydroxylase / blood
  • Steroid 21-Hydroxylase / genetics
  • Virilism / diagnosis

Substances

  • Mineralocorticoids
  • Androstenedione
  • Progesterone
  • 17-alpha-Hydroxyprogesterone
  • Steroid 21-Hydroxylase